Summary by Moomoo AI
On April 5, 2024, NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced its financial results for the year ending December 31, 2023, and provided a business update. The company reported significant clinical results from its Phase 2b PARADIGM ALS trial, where its lead drug candidate, PrimeC, showed a 37.4% slower disease progression in ALS patients compared to placebo. The trial's positive outcomes extend to quality of life and complication-free survival, with plans to present the data at a medical conference and for publication. Financially, NeuroSense experienced an 18% increase in R&D expenses due to higher employee numbers and clinical program costs, while G&A expenses decreased by 20% primarily due to lower share-based compensation and insurance costs. Overall operating expenses slightly...Show More